期刊文献+

姜黄素逆转非小细胞肺癌分子靶向药物耐药的研究进展 被引量:12

Research progress of reversion molecular targeted drug resistance in non-small cell lung cancer by curcumin
下载PDF
导出
摘要 近年来,随着分子生物学的飞速发展,非小细胞肺癌(NSCLC)的分子靶向治疗成为研究的热点。靶向治疗相对于传统化疗具有很大优势,但是在进行靶向治疗过程中不可避免地遇到耐药问题。耐药问题成为了靶向药物对NSCLC患者治疗的重大障碍。姜黄素是姜黄植物根茎提取物的主要活性成分,具有广泛的抗肿瘤等药理活性,一些研究已证实姜黄素能对许多肿瘤的耐药具有逆转作用。然而,姜黄素对靶向药物耐药的逆转作用的报道并不多。该文总结了国内外相关文献,对靶向药物的主要耐药机制和姜黄素对其耐药的相关作用研究进展进行综述。 In recent years,molecular biology has rapidly developed,and molecular targeted therapy of non small cell lung cancer has become a hot spot for the research.Although the targeted therapy has a big advantage compared with traditional chemotherapy,it is inevitable to encounter drug resistance in targeted therapy.Therefore,drug resistance has become the significant obstacle of targeted drugs for the treatment of non small cell lung cancer(NSCLC).Curcumin is the main extract of tumeric rhizome,which harbours a wide range of antitumor activities,and several studies have identified that curcumin exhibits reversion drug resistance against a variety of cancer cells.However,there are few studies on curcumin reversion molecular targeted drug resistance.This review summarizes the recent progress in resistance mechanism of targeted drug and the reversion resistance of curcumin.
作者 于梦迪 王明霞 王海东 YU Meng di;WANG Ming xia;WANG Hai dong(Pharmaceutical Dept, Fourth Hospital of Hebei Medical University, Shijiazhuang050011,China)
出处 《中国药理学通报》 CAS CSCD 北大核心 2017年第12期1633-1637,共5页 Chinese Pharmacological Bulletin
基金 河北省人力资源和社会保障厅留学回国人员科技活动择优资助项目(No 20100313) 河北省中医药管理局科研计划项目(No 2013161)
关键词 分子靶向药物 药物耐药 非小细胞肺癌 姜黄素 耐药机制 逆转耐药 molecular targeted drug drug resistance non small cell lung cancer(NSCLC) curcumin resistance mechanism reversion resistance
  • 相关文献

参考文献11

二级参考文献109

  • 1ERCAN D, ZEJNULLAHU K, YONESAKA K, et al.Amplification of EGFR T790M causes resistance to anirreversible EGFR inhibitor [J]. Oncogene, 2010, 29(16):2346-2356.
  • 2JAIN A, TINDELL C A,LAUX I,et al. Epithelial membraneprotein-1 is a biomarker of gefitinib resistance [J], Proc NatlAcad Sci USA, 2005,102(33): 11858- 11863.
  • 3SUTANI A, NAGAI Y,UDAGAWA K,et al. Gefitinib fornon-small-cell lung cancer patients with epidermal growthfactor receptor gene mutations screened by peptide nucleicacid-locked nucleic acid PCR clamp [J]. Br J Cancer, 2006,95(11): 1483-1489.
  • 4FELIP E,CEDRES S,PERALTA S, et al. Adjuvantchemotherapy in non-small cell lung cancer (NSCLC) [J]. AnnOncol, 2007,18(suppl 9): ix 143-146.
  • 5PATEL B B, GUPTA D,ELLIOTT A A, et al. Curcumin targetsFOLFOX-surviving colon cancer cells via inhibition of EGFRsand IGF-IR [J]. Antivan Res, 2010, 30(2): 319-326.
  • 6DOROTHY W, MYSORE S V, KERRY S, et al. Liposome-encapsulated curcumin suppresses growth of head and necksquamous cell carcinoma in vitro and in xenografts through theinhibition of nuclear factor kB by an AKT-independentpathway [J]. Clin Can Res, 2008,14(19): 6228-6236.
  • 7KIM J H, XU C J, KEUM Y S, et al. Inhibition of EGFRsignaling in human prostate cancer PC-3 cells by combinationtreatment with P-phenylethyl isothiocyanate and curcumin [J].Carcin, 2006, 27(3): 475-482.
  • 8JONES H E, GODDARD L, GEE J M,et al. Insulin-likegrowth factor-1 receptor signaling and acquired resistance togefitinib (ZD1839, Iressa) in human breast and prostate cancercells [J]. Endocr Relat Cancer, 2004, 11(4): 793-814.
  • 9KOKUBO Y, GEMMA A, NORO R, et al. Reduction of PTENprotein and loss of epidermal growth factor receptor genemutation in lung cancer with natural resistance to gefetinib(Iressa) [J]. BrJ Cancer, 2005, 92(9): 1711-1719.
  • 10Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer[J]. Semin Oncol, 2006, 33(4): 369-385.

共引文献95

同被引文献108

引证文献12

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部